CHAMEDITECH, a subsidiary of CHA Biotech, has officially launched its latest scalp care solution, Seltermi Revive HS, in South Korea. The announcement came on June 19, marking a significant addition to the clinical approach toward hair loss treatment.
Designed for professional use in hospitals and clinics, Seltermi Revive HS is formulated to deliver oxygen and essential nutrients directly to hair follicles. The product aims to promote healthier hair growth by revitalizing follicular activity and supporting scalp health — key concerns for those suffering from early to moderate stages of hair thinning.
The launch is timely, as interest in non-surgical and regenerative treatments for hair restoration continues to grow. While traditional hair transplant surgery remains a popular solution, patients are increasingly seeking supplementary or alternative therapies that enhance hair quality and delay the need for more invasive procedures.
Seltermi Revive HS is expected to be used alongside existing treatments and may also benefit individuals undergoing hair transplant recovery, by optimizing the scalp environment and improving outcomes.
This product launch underscores CHAMEDITECH’s growing commitment to biotechnology-based aesthetic and therapeutic solutions. As the demand for hair restoration treatments continues to rise globally, especially in South Korea’s competitive beauty market, Seltermi Revive HS could offer a clinically validated option for managing hair loss more effectively.
For patients curious about hair transplant before and after results, new products like this provide hope that early intervention and integrated care can yield both visual improvement and long-term follicular stability.
Related Topics:
8 Best Hair Loss Treatments for Women That Actually Work
The Most Painless Hair Transplant Methods: Expert Recommendation
Does Cigna Cover Hair Transplant? | A Complete Guide
